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Review Series: Non-Invasive Monitoring of Airway Inflammation in Asthma
Exhaled Nitric Oxide (FeNO)
as a Non-Invasive Marker
of Airway Inflammation
Mitsuru Munakata1,2
ABSTRACT
Nitric oxide (NO), previously very famous for being an environmental pollutant in the field of pulmonary medi-
cine, is now known as the smallest, lightest, and most famed molecule to act as a biological messenger. Fur-
thermore, recent basic researches have revealed the production mechanisms and physiological functions of ni-
tric oxide in the lung, and clinical researches have been clarifying its tight relation to airway inflammation in
asthma. On the bases of this knowledge, fractional nitric oxide (FeNO) has now been introduced as one of the
most practical tools for the diagnosis and management of bronchial asthma.
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INTRODUCTION
Previously known as a toxic molecule listed as an en-
vironmental pollutant, nitric oxide (NO) is now
known to be the smallest, lightest, and most famed
molecule to act as a biological messenger in mam-
mals. NO was first recognized as a physiologically im-
portant molecule in the manuscript written by Fruch-
gott and Zawadzki, entitled “The obligatory role of en-
dothelial cells in the relaxation of arterial smooth
muscle by acetylcholine”, published in Nature in
1980.1 Initially, the factor released from vascular en-
dothelial cells was named as endothelium derived re-
laxing factor (EDRF), and large number of scientists
had been pursued the true feature of EDRF. In 1987,
two groups led by Ignaro and by Moncada, independ-
ently discovered and reported that EDRF is a simple
gaseous molecule called NO.2,3 After the discovery, a
large amount of studies in field of medicine revealed
its many roles in a wide range of pathophysiological
status including cardiovascular, immune, metabolic,
and neurological diseases. For an ordinary person, it
became a very famous physiological mediator of
penile erection and opened the door for the treatment
of impotence.4 In 1992, NO was selected as Molecule
of the Year for a startlingly simple molecule unites
neuroscience, physiology and immunobiology and re-
vised scientists’ understanding of how cells communi-
cate and defend themselves.5 In 1998, the Nobel prize
for Physiology or Medicine was awarded to Doctors,
Furchgott R, Ignarro L, and Murad F.6
In the field of pulmonary medicine, physiological
and pathological roles of NO in lung disease have
also been investigated. Epithelium dependent inhibi-
tion of airway smooth muscle contraction and epithe-
lium dependent relaxation of airway smooth muscle,
similar effect of vascular endothelium to vascular
smooth muscle, have been reported.7,8 These phe-
nomena also suggested the existence of epithelium
derived relaxing factor (EpDRF).9 Since NO is also
confirmed to be a potent smooth muscle relaxing
agent (Fig. 1),10 several pharmacological studies veri-
fying whether EpDRF is also NO were carried out
and confirmed production of NO from airway epithe-
lium.11 In these processes, measurement systems for
NO in exhaled air have been developed.12 By apply-
ing such systems, exhaled NO have been measured
in many pulmonary diseases and significant increase
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Fig.　1　Airway smooth muscle relaxation induced by nitric oxide (NO). Guinea pig tra-
cheal strip was contracted by stimulated by Carbachol (Carb), then 0.1 to 410 ul of satu-
rated solution of NO (estimated concentration 2 mM) was prepared, and was added to the 
tissue bath.  Clear concentration-dependent relaxation was observed (Adapted from refer-
ence 10).
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in exhaled NO of the patients with asthma became
apparent.13,14 Since the measurement is noninvasive
and effort independent, exhaled NO has been much
expected as a new tool for the diagnosis and manage-
ment of asthma, and large efforts have been devoted
on the clinical research.
PRODUCTION AND FUNCTION OF NO IN
THE AIRWAYS
In the respiratory tract, NO is produced by a wide va-
riety of cell types and is generated through conver-
sion of L-arginine to L-citrulline by the action of nitric
oxide synthase (NOS). Three isoforms of NOS are
known: neuronal NOS (NOS I or nNOS), inducible
NOS (NOS II or iNOS), and endothelial NOS (NOS
III or eNOS).15 Two isoforms, nNOS and eNOS, are
expressed constitutively, but iNOS is not normally ex-
pressed in most tissues but is induced in several
types of cells by pro-inflammatory cytokines.16-18 All
three types of NOS isoforms are known to be ex-
pressed in the lung. Endothelial NOS (eNOS) im-
munoreactivity is found in endothelial cells of pulmo-
nary vessels. In addition, it is constitutively expressed
in human bronchial epithelium and in type II pneu-
mocytes.19,20 NO produced by eNOS and released
from endothelial cells in the pulmonary circulation is
speculated to regulate vascular basal tone and coun-
teract hypoxic vasoconstriction.21 Neuronal NOS
(nNOS) is expressed in human airway nerves, includ-
ing those present in the airway smooth muscle,22,23
and is estimated to be a major mediator of the
inhibitory non-adrenergic non-cholinergic nervous
(iNANC) system.24 Co-localization with vasoactive in-
testinal polypeptide (VIP) is also observed.25 Nerves
distributed to submucosal glands also contain nNOS
and NO regulates secretory function of the
glands.22,26 In the lung, iNOS (or NOS II) is known to
be expressed in macrophages,27 epithelial cells,28-30
type II pneumocytes,31,32 endothelial cells,33 airway
and vascular smooth muscle,34 mast cells,35 neutro-
phils,36 chondrocytes,23 and fibroblast.37 Usually,
iNOS in these cells is expressed when stimulated by
endogenous mediators such as chemokines and cy-
tokines, and by exogenous stimulant such as bacte-
rial toxins, viruses, allergens, etc. Constitutive ex-
pression of iNOS in airway epithelial cells and rapid
loss of its expression after removal of the epithelial
cells from the in vivo airway environment were re-
ported only in humans and suggest that the expres-
sion is dependent upon conditions andor factors pre-
sent in the airway.38 iNOS derived NO is also specu-
lated to regulate both airway smooth muscle tone and
inflammatory responses.
MEASUREMENT OF EXHALED NO
The presence of NO in the exhaled air of humans was
demonstrated by chemiluminescence, diazotization
and mass spectrometry in 1991.12 Thereafter, several
measurement systems have been developed. The
most commonly used system is chemiluminescence,
and in Japan, two types are available; NOA280i (Sev-
ers, GE Analytical Instruments, Boulder, USA) and
NA623N (Chest MI, Tokyo, Japan). These can be ap-
plied for both online and offline measurement of frac-
tional exhaled NO (FeNO) in ppb. With these two
types, we can get almost the same FeNO values.39-42
It is known that FeNO is strongly affected by expira-
tory flow rate, FeNO levels in dead space air are high,
and those in nasal cavities are very high. Therefore,
several cautions should be kept in mind to get rea-
sonable FeNO values. These cautions are included in
American Thoracic Society (ATS) and European Res-
piratory Society (ERS) recommendations for the
measurement of FeNO,43,44 and following these rec-
ommendations is very important when FeNO is
measured with these analyzers.
Another NO measurement system is the electro-
chemical method. The merits of the system are its
compact size and portability. In Japan, two types of
analyzers, NIOX MINO (Aerocrine, Stockholm, Swe-
den) and NObreath (Bedfont Scientific, Kent, UK),
are available. There are some differences in FeNO
levels measured by these analyzers when compared
to a chemiluminescence analyzer. Differences of
FeNO levels measured by different analyzers have
been examined and conversion equations are also
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available.39-42 Several attempts to separate alveolar
NO from airway NO have been performed by measur-
ing FeNO at multiple exhalation flow rates,45-48 how-
ever, it seems very difficult to apply such methods to
clinical medicine and they might be useful as re-
search tools.
NO AND AIRWAY INFLAMMATION IN
ASTHMA
Asthma is a syndrome characterized by the presence
of two physiological characteristics, reversible airflow
limitation and airway hyperresponsiveness with respi-
ratory symptoms. However, a recent advance in
asthma research revealed the importance of airway
inflammation existing behind these physiological
characteristics. According to such progress in the
concept of asthma, diagnosis and treatment strategies
have been changing dramatically. One of the most
prominent examples is the introduction of anti-
inflammatory therapy with ICS, resulting in the pro-
nounced the improvement in control and quality of
life of the patients, and a dramatic reduction in the
number of emergency room visit and deaths of the
patients in Japan.
The recognition of the important roles of airway in-
flammation in asthma also promoted the development
of new technology to evaluate airway inflammation in
asthma. In these processes, a FeNO measurement
was recognized as the most anticipated candidate. In
early 1990s, significant increase in FeNO of ICS naïve
patients with asthma, and decreased FeNO after ICS
treatment was revealed,13,14 suggesting the relation-
ship between airway inflammation and elevation of
FeNO. Hamid et al. applied immune-histochemical
methods for bronchial biopsy specimen to investigate
the presence of NOS in asthma. Immunoreactivity to
iNOS was observed in the epithelium and some in-
flammatory cells in 22 of 23 biopsies from asthmatics,
but in only 2 of 20 controls.49 Guo et al. also exam-
ined iNOS expression by mRNA and protein assay
and revealed that human airway epithelium has abun-
dant expression of iNOS due to continuous transcrip-
tional activation of the gene in vivo, and that individu-
als with asthma have higher than normal NO concen-
trations and increased iNOS mRNA and protein due
to transcriptional regulation through activation of
STAT1.50 In addition, they revealed decreased ex-
pression of iNOS mRNA in asthmatics receiving
ICS.50 Redington et al. also examined iNOS expres-
sion in the airway epithelium and revealed enhanced
expression in asthmatic subjects and regulation by
corticosteroid treatment.51
The regulation mechanisms of iNOS expression
are far from full elucidation. Although abundant ex-
pression of iNOS is observed in human airway epithe-
lium, it will instantly disappear when these cells are
cultured ex vivo,38 suggesting the existence of in vivo
factors or stimuli in the airway. In other types of cells,
iNOS expression is only observed after stimulation
with cytokines such as IFN-γ, IL-1β, andor TNF-α.52
Guo et al. revealed that a combination of IFN-γIL-4,
which occurs naturally in lung epithelial lining fluid,
leads to maintenance of iNOS expression in human
airway epithelium through production of soluble me-
diators and stabilization of mRNA.53 Alving and Mali-
novschi suggested a possible model of iNOS regula-
tion of human airway from the results of recent stud-
ies54 (Fig. 2). In healthy subjects (Fig. 2a), continu-
ous expression of iNOS is maintained by IFN-γ,
which normally exists in the respiratory tract. In this
process, induction of unidentified soluble mediators
by IFN-γ and the subsequent activation of the JAK
STA pathway are considered to be important.55 In
asthmatic airways (Fig. 2b), different regulation
mechanisms are estimated (Fig. 2b). Initially, Th2 cy-
tokines such as IL-4 and IL-13 were recognized to
down-regulate iNOS expression.56 However, several
recent studies revealed that IL-4 and IL-13 actually in-
duce iNOS expression in human airway epithelial
cells in reasonable medium conditions through the
STAT-6 pathway.50,53,57,58
There are several epidemiological evidences sug-
gesting the relation between allergic airway inflam-
mation and increased FeNO. Saito et al. examined
FeNO levels, pulmonary function, and serum total
and antigen specific IgE levels in 278 normal school
children aged 10 to 12.59 There are statistically signifi-
cant positive correlations between FeNO and total
IgE or mite specific IgE, and significant negative cor-
relations between FeNO and FEV1FVC. In addition,
FeNO was determined by means of multiple logistic
regression analysis to be the best predictor for recur-
rent wheeze, suggesting the relationship between al-
lergic airway inflammation and FeNO levels. They
also obtained the same results when they examined
280 normal adults aged 18 to 82 who received annual
health check.60 Moody et al. revealed that the in-
crease in FeNO is associated with house dust mite
sensitivity in asymptomatic subjects.61 Additionally,
some atopic subjects without symptoms and airway
hyperresponsiveness have airway eosinophilc inflam-
mation.62 These findings support the tight relation-
ship between increase of FeNO levels and allergic air-
way inflammation.
NO AS A DIAGNOSTIC TOOL OF ASTHMA
Traditionally, asthma has been characterized by res-
piratory symptoms such as cough, wheeze, and dysp-
nea, reversible airflow limitation, and non-specific air-
way hyperresponsiveness.63,64 These are evaluated by
pulmonary function tests before and after inhalation
of bronchodilators such as β-adrenergic receptor ago-
nists, and bronchial challenge test with bronchocon-
trictors such as histamine and acetylcholine.64 For
the airway inflammation, trans-bronchial biopsy
(TBB) and brochoalveolar lavage (BAL) under the fi-
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Fig.　2　A possible model of iNOS regulation of human airway. a) normal healthy 
airway, b) asthmatic airway (Adapted from reference 54).
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beroptic bronchoscopic examination are applied. Re-
cently, cell sorting of sputum induced by the inhala-
tion of hypertonic saline has also been utilized. How-
ever, these methods are relatively invasive and some-
times induce asthma attacks. It is therefore difficult to
apply widely in general clinical practice.
Because of the tight relation between FeNO and al-
lergic airway inflammation and its non-invasiveness,
attempts to use FeNO as a non-invasive tool for
asthma diagnosis have been carried out in various
clinical settings. Sato et al. examined 71 consecutive
patients who visited out-patient clinics by complain-
ing chronic cough continuing more than 3 weeks.65
They examined FeNO, pulmonary function, serum
IgE, methacholine airway responsiveness and in-
duced sputum. FeNO is significantly higher in pa-
tients with asthma and cough variant asthma com-
pared to other diseases including COPD and eosino-
philic pneumonia without asthma, suggesting the
usefulness of FeNO measurement in the diagnosis of
asthma in patients with chronic cough. Cut-off value
for FeNO for the diagnosis of asthma was 38.8 ppb
with sensitivity of 79.2% and specificity of 91.3%. Simi-
lar results were also reported in patients with chronic
cough by Chatkin et al., Fujimura et al., and Kowal et
al..66-68
For the patients with non-specific respiratory symp-
toms and suspected to having asthma, Smith et al. ex-
amined FeNO and sputum eosinophils in addition to
conventional peak expiratory flow and spirometric pa-
rameters before and after bronchodilator treatment.69
They observed the overall superiority of FeNO meas-
urements and induced sputum analysis in the diagno-
sis of asthma compared with conventional tests. Du-
pont et al. also reported the usefulness of FeNO in
160 asthmatic patients diagnosed by the presence of
reversible airflow obstruction (delta FEV1 > 12%) and
histamine airway hyperresponsiveness (PC20 < 8.0
mgml).70 Their cut-off level of FeNO at expiratory
flow rate of 200 mls (FeNO200) was 16.0 ppb with
the sensitivity of 69.4% and specificity of 90.0%. For-
tuna et al. also reported that the diagnostic accuracy
of FeNO measurement was superior to that of the
standard diagnostic spirometry in patients with symp-
toms suggestive of asthma.71 Fukuhara et al. recently
reported the results of their prospective validation
Exhaled Nitric Oxide in Asthma
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Fig.　3　The cut-off levels of fractional exhaled nitric oxide (FeNO) for diagnosing asthma obtained from 3 inde-
pendent studies. a) for 277 school children, b) for 280 adult volunteers, c) for 71 patients with chronic cough 
(Adapted from reference 42).
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study of asthma screening criteria based on subjec-
tive symptoms and FeNO at expiratory flow rate of 50
mlsec (FeNO50); i) recurrent cough, wheezeing, or
dyspnea; ii) FeNO50 > 40 ppb, iii) exclusion of other
lung diseases.42 A cut-off value of 40 ppb was deter-
mined by the results of their 3 previous independent
studies on school children, normal adults, and pa-
tients with prolonged cough (Fig. 3).59,60,65 When
compared to conventional asthma diagnostic criteria
based on GINA and JGL guidelines,63,64 FeNO based
criteria showed good sensitivity, specificity, and a
concordance rate (k) (78.6%, 89.5%, and 0.62, respec-
tively). However, 9 of 42 patients were misdiagnosed
as not having asthma by FeNO based criteria, and 7
of these 9 patients were non-atopic according to their
IgE levels. From these results, they suggested that
FeNO could be used as a tool for the non-invasive ac-
curate diagnosis of asthma, particularly in atopic pa-
tients in daily clinical practice.
NO AS A CONTROL TOOL OF ASTHMA
Understanding that the most basic event in asthma is
airway inflammation and the tight correlation be-
tween FeNO and airway inflammation has motivated
the application of FeNO as a monitoring tool for
asthma control. In 2005, Smith et al. did a single-
blind, placebo-controlled trial of adult asthmatics to
examine the usefulness of FeNO measurements for
the adjustment of ICS doses. With the FeNO based
strategy, the maintenance doses of ICS were signifi-
cantly reduced without compromising asthma control
compared to those with an algorithm based on con-
ventional guidelines.72 In the same year, Pijnenburg
et al. did a randomized controlled trial to examine the
usefulness of FeNO for the titration of ICS in atopic
children with asthma. They also found that FeNO im-
proved airway hyperresponsiveness and inflammation
without elevating the ICS doses.73 Following these
studies, several consecutive studies were conducted
and controversial results were reported. For the adult
asthmatics, Shaw et al. reported that a treatment
strategy based on FeNO measurement did not result
in a large reduction in asthma exacerbation or in the
total amount of ICS therapy used over 12 months,
compared with the current asthma guideline.74 But
when the results were pored over precisely, in the in-
itial several months, the required dose of ICS was
higher in the FeNO based group compared to the
control group, the dose gradually declined and the fi-
nal daily dose of ICS was significantly lower in the
FeNO based group compared to the control group
(average; 557 ugday and 895 ugday, respectively, p
< 0.028). More recently, Powel et al. carried out a
double-blinded, randomized controlled trial to exam-
ined the usefulness of asthma management in preg-
nancy guided by FeNO. They revealed that asthma
exacerbations during pregnancy can be significantly
reduce with a validated FeNO-based treatment algo-
rithm.75 For adolescents and young adults, Szefler et
al. did the largest randomized controlled trial to date
with 780 patients with asthma to examine the useful-
ness of FeNO-based asthma management in addition
to guideline-based treatment. They concluded that
the addition of FeNO as an indicator of asthma con-
trol resulted in higher doses of ICS, without clinically
important improvements in symptomatic asthma con-
trol.76 But the subgroup analyses of the patients with
a higher number of positive skin tests or those with
serum nonspecific IgE higher than 460 kUL re-
vealed that the FeNO monitoring group had signifi-
cantly fewer maximum days with symptoms in 2
weeks than that of the control group (0.84 and 0.51, p
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< 0.024 and p < 0.007, respectively). As shown in the
previous section, FeNO is suggested to be a very use-
ful tool to monitor airway inflammation in atopic sub-
jects. From these facts, it is suggested that applica-
tion of FeNO as a tool for asthma control might be
limited to the patients with atopic asthma.
Another point that should be borne in mind is the
fact that the period of previously introduced studies
were only up to 12 months. Sont et al. compared the
difference in histopathologic outcome of asthma
when using airway hyperesponsiveness as an addi-
tional guide to long-term treatment. They demon-
strated that the examined strategy group showed a
greater reduction in thickness of the subepithelial re-
ticular layer compared to the reference strategy
group, suggesting a role for the monitoring of airway
hyperresponsiveness or other surrogate makers of in-
flammation in preventing airway remodeling.77 Long-
term usefulness of FeNO as a monitoring tool for
asthma control, whether it could be helpful in preven-
tion of airway remodeling or in decreasing annual de-
cline in FEV1, needs to be examined.
FUTURE DIRECTIONS
As noted above, FeNO is a very useful diagnostic tool
and control monitoring maker of asthma. Usefulness
of FeNO in asthma management is probably better
than spirogram, induced sputum, and AHR test, be-
cause of its non-invasiveness, effort independency,
measurement simplicity, and reproducibility. Al-
though the FeNO analyzer has not been approved as
a medical device, it will be widely used as a conven-
ient clinical tool for asthma management in the near
future in Japan.
The FeNO analyzer has been used as a clinical re-
search tools and wide application of FeNO in the
clinical setting revealed the issues that should be
solved before its clinical application. Now, many re-
searchers recognize that there is a minor population
of subjects with very high levels of FeNO without res-
piratory symptoms, and that there are asthmatics
with all asthmatic symptoms but with normal FeNO
levels. The mechanisms behind these phenomena are
unclear, meaning that the production mechanisms of
NO in the airway and lung parenchyma have not
been thoroughly clarified. Additional point is that, al-
though the ATSERS guideline was established to
standardize the FeNO measurements,43 there are
variations in FeNO values measured by different ana-
lyzers.41,42 It also affects the determination FeNO cut-
off levels for the diagnosis and control of asthma. In
addition, to be used widely in the clinical practice, the
development of handier, more accurate, less expen-
sive measurement systems is required. Furthermore,
not only more practical studies but also more basic
studies will be warranted.
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